4See Pub. L. No. 108-173, 117 Stat. 2066 (codified as amended in scattered sections of 21 U.S.C.).
5See Lisa Barons. The lealitv of reverse oavment settlements in Param'aoh IV disoutes. CITE AS: Intellectual Asset Mana,ement.2012.7/8.
6See FTC, Generic Drug Entry Prior to Patent Expiration: An FTC Study, 24, 25 & nn.2-3(2002), available at , http://www.flc.gov/os/2002/07/ generiedrugstudy.pdf.
7,N. Pac. Ry. Co. v. United States, 356 U.S.1, 5 (1958).
8See In re Tamoxifen Citrate Antitrust Litig., 466 F.3d 187, 193 (2d Cir. 2006).
9See Antitrust Guidelines for the Licensing of Intellectual Property, Issued by the U.S. Department of Justice and the Federal Trade Commission.1995,4.
10See Valley Drug Co. ,. Geneva Pharms., Inc., 344 F.3d 1294 (1 lth Cir. 2003).
